Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Alatrofloxacin
2. Alatrofloxacin Mesylate
3. Cp 116,517
4. Cp 116517
5. Cp-116,517
6. Cp-116517
7. Trovan
1. Trovan
2. 147059-75-4
3. Trovafloxacin Methanesulfonate
4. Trovafloxacin Mesilate
5. Trovafloxacin Monomethanesulfonate
6. Trovafloxacin (mesylate)
7. Cp-99219-27
8. Trovafloxacin Mesylate [usan]
9. 0p1lko80wn
10. Cp 99219
11. Chebi:77568
12. Cp-99,219-27
13. Dsstox_cid_25701
14. Dsstox_rid_81073
15. Dsstox_gsid_45701
16. 7-((1r,5s,6s)-6-amino-3-azabicyclo(3.1.0)hex-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic Acid, Monomethanesulfonate
17. Trovafloxacin Mesylate (usan)
18. 1,8-naphthyridine-3-carboxylic Acid, 7-[(1alpha,5alpha,6alpha)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-, Methanesulfonate (1:1)
19. Rel-7-((1r,5s,6s)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic Acid Compound With Methanesulfonic Acid (1:1)
20. Cas-147059-75-4
21. Unii-0p1lko80wn
22. Turvel
23. Trovafloxacin Sulfate
24. Trovan (tn)
25. Cp 99219 Mesylate
26. Trovafloxacin Monomesylate
27. Ncgc00064532-02
28. Cp 99219-27
29. Schembl40874
30. Schembl40875
31. Chembl1200779
32. Dtxsid0045701
33. Hms3260e16
34. Tox21_110980
35. Tox21_500107
36. Trovafloxacin Mesylate [vandf]
37. Akos000280396
38. Akos015914051
39. Tox21_110980_1
40. Trovafloxacin Mesilate [mart.]
41. Ccg-221411
42. Trovafloxacin Mesilate [who-dd]
43. Trovafloxacin Mesylate, >98% (hplc)
44. Ncgc00260792-01
45. Ncgc00263538-01
46. 1,8-naphthyridine-3-carboxylic Acid, 7-(6-amino-3-azabicyclo(3.1.0)hex-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-(1alpha,5alpha,6alpha)-, Monomethanesulfonate
47. Trovafloxacin Methanesulfonate [mi]
48. Hy-103399
49. Trovafloxacin Mesylate [orange Book]
50. Cs-0027824
51. D02123
52. E98675
53. J-008308
54. J-690188
55. Q27147183
56. (1r,5s,6s)-3-[6-carboxy-8-(2,4-difluorophenyl)-3-fluoro-5-oxo-5,8-dihydro-1,8-naphthyridin-2-yl]-3-azabicyclo[3.1.0]hexan-6-aminium Methanesulfonate
57. 1,8-naphthyridine-3-carboxylic Acid, 7-((1.alpha.,5.alpha.,6.alpha.)-6-amino-3-azabicyclo(3.1.0)hex-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-, Methanesulfonate (1:1)
58. 1,8-naphthyridine-3-carboxylic Acid, 7-(6-amino-3-azabicyclo(3.1.0)hex-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-(1.alpha.,5.alpha.,6.alpha.)- Monomethanesulfonate
59. 171335-83-4
60. 7-((1r,5s,6s)-6-amino-3-azabicyclo[3.1.0]hexan-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic Acid Compound With Methanesulfonic Acid (1:1)
61. 7-[(1?,5?,6?)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic Acid Mesylate
62. 7-[(1r,5s,6s)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic Acid Methanesulfonate
| Molecular Weight | 512.5 g/mol |
|---|---|
| Molecular Formula | C21H19F3N4O6S |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 13 |
| Rotatable Bond Count | 3 |
| Exact Mass | 512.09774000 g/mol |
| Monoisotopic Mass | 512.09774000 g/mol |
| Topological Polar Surface Area | 163 Ų |
| Heavy Atom Count | 35 |
| Formal Charge | 0 |
| Complexity | 863 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Trovafloxacin is a synthetic broad spectrum quinolone antibacterial agent indicated for the treatment of the following infections in adults:
- Pneumonia: Community Acquired Pneumonia and Nosocomial Pneumonia (mild, moderate, and severe).
Note: Efficacy in patients with very severe nosocomial pneumonia and in particular infections due to less susceptible pathogens e. g. P. aeruginosa, has not been established. See also section 4. 2.
- Acute Exacerbations of Chronic Bronchitis
- Acute Sinusitis
- Complicated Intra-abdominal Infections and Acute Pelvic Infections
- Salpingitis
- Uncomplicated Gonococcal Urethritis and Cervicitis
- Chlamydial Cervicitis
- Complicated Skin and Soft Tissue Infections
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Trovafloxacin is a synthetic broad spectrum quinolone antibacterial agent indicated for the treatment of the following infections in adults:
Pneumonia:
- Community Acquired Pneumonia and Nosocomial Pneumonia (mild, moderate, and severe).
Note: Efficacy in patients with very severe nosocomial pneumonia and in particular infections due to less susceptible pathogens e. g. P. aeruginosa, has not been established. See also section 4. 2.
- Acute Exacerbations of Chronic Bronchitis
- Acute Sinusitis
- Complicated Intra-abdominal Infections and Acute Pelvic Infections
- Salpingitis
- Uncomplicated Gonococcal Urethritis and Cervicitis
- Chlamydial Cervicitis
- Complicated Skin and Soft Tissue Infections
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Topoisomerase II Inhibitors
Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)
Anti-Infective Agents
Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)
J01MA13
J01MA13
Market Place
ABOUT THIS PAGE
15
PharmaCompass offers a list of Trovafloxacin Mesylate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Trovafloxacin Mesylate manufacturer or Trovafloxacin Mesylate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Trovafloxacin Mesylate manufacturer or Trovafloxacin Mesylate supplier.
PharmaCompass also assists you with knowing the Trovafloxacin Mesylate API Price utilized in the formulation of products. Trovafloxacin Mesylate API Price is not always fixed or binding as the Trovafloxacin Mesylate Price is obtained through a variety of data sources. The Trovafloxacin Mesylate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Trovafloxacin Mesylate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Trovafloxacin Mesylate, including repackagers and relabelers. The FDA regulates Trovafloxacin Mesylate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Trovafloxacin Mesylate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Trovafloxacin Mesylate supplier is an individual or a company that provides Trovafloxacin Mesylate active pharmaceutical ingredient (API) or Trovafloxacin Mesylate finished formulations upon request. The Trovafloxacin Mesylate suppliers may include Trovafloxacin Mesylate API manufacturers, exporters, distributors and traders.
Trovafloxacin Mesylate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Trovafloxacin Mesylate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Trovafloxacin Mesylate GMP manufacturer or Trovafloxacin Mesylate GMP API supplier for your needs.
A Trovafloxacin Mesylate CoA (Certificate of Analysis) is a formal document that attests to Trovafloxacin Mesylate's compliance with Trovafloxacin Mesylate specifications and serves as a tool for batch-level quality control.
Trovafloxacin Mesylate CoA mostly includes findings from lab analyses of a specific batch. For each Trovafloxacin Mesylate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Trovafloxacin Mesylate may be tested according to a variety of international standards, such as European Pharmacopoeia (Trovafloxacin Mesylate EP), Trovafloxacin Mesylate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Trovafloxacin Mesylate USP).
